info@nano-mab.com

NanoMab believes the strategic collaborations between the respective parties will expedite development of NM-01 and ensure its diagnostic and therapeutic potential can soon benefit patients in the battle against PD-L1 expressing malignancies. Read the full press release here: https://bit.ly/3zBznbn

London, May 17, 2022 - NanoMab Technology Limited, a privately held biopharmaceutical company focussing on the development of next generation radiopharmaceuticals for cancer precision therapies, today announced the dosing of the first patient in a phase II clinical trial in partnership with Lantheus and King’s College London. The phase II trial is a non-randomised, non-blinded, [...]

London, April 29th, 2022 - NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies is thrilled to announce the well-deserved promotion of Dr. Gitasha Chand to Managing Director and Dr. Levente Meszaros to Director of Technical Operations of NanoMab Technology (UK) Ltd. Dr. Chand, who most recently held the position of [...]

London, April 12th, 2022 - NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies is delighted to announce that over the course of the last two quarters it has taken the next steps forward in its commitment to developing next generation pharmaceuticals by forming exclusive licensing agreements with Radiopharm Theranostics (ASX: [...]

Thanks to the great support from our collaboration partner LMI , NanoMab has reached another milestone with this Tc-99m NM01 DMF filing with FDA after its MHRA Approval into Phase 2 trial in UK ! Lantheus' Press Release  

Why next generation radiopharma-ceuticals will play a key role in the quest for precision medicine. https://www.sciencedirect.com/science/article/pii/S1359644620304190  

London, November 4th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had received CTA Acceptance from the Medicines Healthcare products Regulatory Agency (MHRA) to carry out a Phase II clinical Study for its NM-01 product. The study (“PELICAN”) will investigate the assessment of programmed death [...]

London, October 27th, 2020: NanoMab Technology Limited, a privately held biopharmaceutical company focussing on precision cancer therapies, today announced that it had signed Heads of Terms with OncoBeta® GmbH, a supplier of Tungsten-188/ Rhenium-188 generators for the production of high-energy beta emitting Rhenium-188, as well as a commercial stage medical device company specialized in innovative [...]

London, October 8th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that in collaboration with King’s College London and Guys & St Thomas’ Hospitals, it has commenced a mechanistic study to noninvasively assess PD-L1 expression using 99mTc-NM-01 as a SPECT/CT radiotracer. Professor Gary Cook, Professor of PET [...]

London, September 9th, 2020:  NanoMab Technology Limited, a privately held biopharmaceutical company focussing on cancer precision therapies, today announced that it had submitted a request to the MHRA for authorisation for a Phase II Clinical Study Protocol for its NM-01 product. The study will investigate the assessment of programmed death ligand 1 (PD-L1) expression using [...]